Old Web
English
Sign In
Acemap
>
authorDetail
>
T. Haas
T. Haas
Novartis
Everolimus
Medicine
Renal cell carcinoma
Oncology
Internal medicine
5
Papers
38
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma
2012
Journal of Biopharmaceutical Statistics
P. Korhonen
E. Zuber
Michael Branson
N. Hollaender
N. Yateman
T. Katiskalahti
David Lebwohl
T. Haas
Show All
Source
Cite
Save
Citations (27)
Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial.
2010
Journal of Clinical Oncology
P. Korhonen
Elisabetta Malangone
Steven Sherman
Roman Casciano
Robert J. Motzer
Jean-Francois Baladi
T. Haas
E. Zuber
Andrea Kay
David Lebwohl
Show All
Source
Cite
Save
Citations (7)
Correcting overall survival (OS) effect for the impact of cross-over via rank preserving structural failure time (RPSFT) model: Case of mRCC RECORD-1 trial of everolimus (EVE).
2010
Journal of Clinical Oncology
E. Zuber
P. Korhonen
Michael Branson
N. Hollaender
T. Katiskalahti
David Lebwohl
T. Haas
Show All
Source
Cite
Save
Citations (0)
1